\BOOKMARK [0][-]{chapter*.2}{Abstract}{}% 1
\BOOKMARK [0][-]{chapter*.3}{Acknowledgements}{}% 2
\BOOKMARK [0][-]{chapter*.4}{Declarations}{}% 3
\BOOKMARK [0][-]{chapter*.4}{Contents}{}% 4
\BOOKMARK [0][-]{chapter*.6}{List of Figures}{}% 5
\BOOKMARK [0][-]{chapter*.7}{List of Tables}{}% 6
\BOOKMARK [0][-]{chapter*.8}{Abbreviations}{}% 7
\BOOKMARK [0][-]{chapter.1}{Introduction}{}% 8
\BOOKMARK [1][-]{section.1.1}{Psoriasis and psoriatic arthritis}{chapter.1}% 9
\BOOKMARK [2][-]{subsection.1.1.1}{Epidemiology and global impact}{section.1.1}% 10
\BOOKMARK [2][-]{subsection.1.1.2}{Psoriasis and inflammatory dermatoses}{section.1.1}% 11
\BOOKMARK [2][-]{subsection.1.1.3}{PsA and spondyloarthropathies}{section.1.1}% 12
\BOOKMARK [1][-]{section.1.2}{Pathophysiology of psoriasis and psoriatic arthritis}{chapter.1}% 13
\BOOKMARK [2][-]{subsection.1.2.1}{Clinical presentation and diagnosis}{section.1.2}% 14
\BOOKMARK [2][-]{subsection.1.2.2}{Aetiology of psoriasis and PsA}{section.1.2}% 15
\BOOKMARK [2][-]{subsection.1.2.3}{Cell types involved in psoriasis and PsA pathogenesis}{section.1.2}% 16
\BOOKMARK [2][-]{subsection.1.2.4}{Therapeutic intervention}{section.1.2}% 17
\BOOKMARK [1][-]{section.1.3}{Genetics of psoriasis and psoriatic arthritis}{chapter.1}% 18
\BOOKMARK [2][-]{subsection.1.3.1}{Heritability}{section.1.3}% 19
\BOOKMARK [2][-]{subsection.1.3.2}{Genome-wide association studies}{section.1.3}% 20
\BOOKMARK [2][-]{subsection.1.3.3}{Relevance of non-coding variants in disease susceptibility}{section.1.3}% 21
\BOOKMARK [2][-]{subsection.1.3.4}{The role of GWAS in highlighting immune-relevant cell types and pathways}{section.1.3}% 22
\BOOKMARK [2][-]{subsection.1.3.5}{Psoriasis and PsA: the same or distinct disease entities}{section.1.3}% 23
\BOOKMARK [2][-]{subsection.1.3.6}{Limitations of GWAS}{section.1.3}% 24
\BOOKMARK [1][-]{section.1.4}{Functional interpretation of GWAS in complex diseases}{chapter.1}% 25
\BOOKMARK [2][-]{subsection.1.4.1}{Overcoming GWAS limitations}{section.1.4}% 26
\BOOKMARK [2][-]{subsection.1.4.2}{Understanding the epigenetic landscape in complex diseases}{section.1.4}% 27
\BOOKMARK [2][-]{subsection.1.4.3}{The chromatin landscape}{section.1.4}% 28
\BOOKMARK [2][-]{subsection.1.4.4}{Transcriptional profiles in disease}{section.1.4}% 29
\BOOKMARK [2][-]{subsection.1.4.5}{Transcriptional regulation in complex diseases}{section.1.4}% 30
\BOOKMARK [2][-]{subsection.1.4.6}{The use of fine-mapping to prioritise functional causal variants}{section.1.4}% 31
\BOOKMARK [2][-]{subsection.1.4.7}{Generation, integration and interpretation of genomic data}{section.1.4}% 32
\BOOKMARK [2][-]{subsection.1.4.8}{Aims and objectives}{section.1.4}% 33
\BOOKMARK [0][-]{chapter.2}{Material and Methods}{}% 34
\BOOKMARK [1][-]{section.2.1}{Ethical approval and recruitment of study participants}{chapter.2}% 35
\BOOKMARK [2][-]{subsection.2.1.1}{Psoriasis patient recruitment}{section.2.1}% 36
\BOOKMARK [2][-]{subsection.2.1.2}{PsA patient recruitment}{section.2.1}% 37
\BOOKMARK [2][-]{subsection.2.1.3}{Healthy volunteer recruitment}{section.2.1}% 38
\BOOKMARK [1][-]{section.2.2}{Sample processing}{chapter.2}% 39
\BOOKMARK [2][-]{subsection.2.2.1}{PBMCs and synovial fluid cells isolation}{section.2.2}% 40
\BOOKMARK [2][-]{subsection.2.2.2}{Skin biopsies processing and adherence assays}{section.2.2}% 41
\BOOKMARK [2][-]{subsection.2.2.3}{Fixation, cryopreservation and cell culture}{section.2.2}% 42
\BOOKMARK [2][-]{subsection.2.2.4}{Primary cell isolation using magnetic-activated cell sorting}{section.2.2}% 43
\BOOKMARK [2][-]{subsection.2.2.5}{Primary cell isolation using fluorescence-activated cell sorting}{section.2.2}% 44
\BOOKMARK [1][-]{section.2.3}{Experimental protocols}{chapter.2}% 45
\BOOKMARK [2][-]{subsection.2.3.1}{ATAC - Chromatin Accessibility}{section.2.3}% 46
\BOOKMARK [2][-]{subsection.2.3.2}{Chromatin immunoprecipitation with sequencing library preparation by Tn5 transposase}{section.2.3}% 47
\BOOKMARK [2][-]{subsection.2.3.3}{RNA extraction and gene expression quantification}{section.2.3}% 48
\BOOKMARK [2][-]{subsection.2.3.4}{DNA extraction and rs4672405 genotyping}{section.2.3}% 49
\BOOKMARK [2][-]{subsection.2.3.5}{Mass cytometry using cytometry by time of flight \(CyTOF\)}{section.2.3}% 50
\BOOKMARK [1][-]{section.2.4}{Computational and statistical analysis}{chapter.2}% 51
\BOOKMARK [2][-]{subsection.2.4.1}{ATAC data analysis}{section.2.4}% 52
\BOOKMARK [2][-]{subsection.2.4.2}{ChIPm data analysis}{section.2.4}% 53
\BOOKMARK [2][-]{subsection.2.4.3}{Gene expression analysis}{section.2.4}% 54
\BOOKMARK [2][-]{subsection.2.4.4}{Genomic region annotation, enrichment analysis and pathway visualisation}{section.2.4}% 55
\BOOKMARK [2][-]{subsection.2.4.5}{Statistical fine-mapping}{section.2.4}% 56
\BOOKMARK [2][-]{subsection.2.4.6}{Mass cytometry data analysis}{section.2.4}% 57
\BOOKMARK [0][-]{chapter.3}{Establishing laboratory methods and analytical tools to assess genome-wide chromatin accessibility in clinical samples}{}% 58
\BOOKMARK [1][-]{section.3.1}{Introduction}{chapter.3}% 59
\BOOKMARK [2][-]{subsection.3.1.1}{Principle of ATAC-seq and compatibility with clinical samples}{section.3.1}% 60
\BOOKMARK [2][-]{subsection.3.1.2}{ATAC-seq limitations and advances in optimisation}{section.3.1}% 61
\BOOKMARK [2][-]{subsection.3.1.3}{Challenges of ATAC data analysis}{section.3.1}% 62
\BOOKMARK [2][-]{subsection.3.1.4}{The challenge of working with clinical samples}{section.3.1}% 63
\BOOKMARK [2][-]{subsection.3.1.5}{Aims}{section.3.1}% 64
\BOOKMARK [1][-]{section.3.2}{Results}{chapter.3}% 65
\BOOKMARK [2][-]{subsection.3.2.1}{Establishment of an ATAC-seq data analysis pipeline}{section.3.2}% 66
\BOOKMARK [2][-]{subsection.3.2.2}{Assessment of ATAC-seq transposition times in relevant cell types}{section.3.2}% 67
\BOOKMARK [2][-]{subsection.3.2.3}{Comparison of ATAC-seq with Fast-ATAC protocol}{section.3.2}% 68
\BOOKMARK [2][-]{subsection.3.2.4}{Limitations of ATAC-seq and Fast-ATAC to assess chromatin accessibility in keratinocytes}{section.3.2}% 69
\BOOKMARK [2][-]{subsection.3.2.5}{Effect of cryopreservation and fixation in the chromatin landscape of immune primary cells}{section.3.2}% 70
\BOOKMARK [1][-]{section.3.3}{Discussion}{chapter.3}% 71
\BOOKMARK [2][-]{subsection.3.3.1}{ATAC: methodological aspects and pipeline establishment}{section.3.3}% 72
\BOOKMARK [2][-]{subsection.3.3.2}{The challenges of performing differential chromatin accessibility analysis}{section.3.3}% 73
\BOOKMARK [2][-]{subsection.3.3.3}{Studying the chromatin landscape from psoriasis skin biopsies}{section.3.3}% 74
\BOOKMARK [2][-]{subsection.3.3.4}{Characterisation of the effect of preservative techniques in the chromatin landscape}{section.3.3}% 75
\BOOKMARK [2][-]{subsection.3.3.5}{Limitations}{section.3.3}% 76
\BOOKMARK [1][-]{section.3.4}{Conclusions}{chapter.3}% 77
\BOOKMARK [0][-]{chapter.4}{Defining the genome-wide chromatin accessibility landscape and gene expression profile in psoriasis}{}% 78
\BOOKMARK [1][-]{section.4.1}{Introduction}{chapter.4}% 79
\BOOKMARK [2][-]{subsection.4.1.1}{The systemic and skin-specific manifestations of psoriasis}{section.4.1}% 80
\BOOKMARK [2][-]{subsection.4.1.2}{The personalised epigenome in disease}{section.4.1}% 81
\BOOKMARK [2][-]{subsection.4.1.3}{Transcriptional profiles in psoriasis}{section.4.1}% 82
\BOOKMARK [2][-]{subsection.4.1.4}{Chromatin accessibility, gene expression and genetic variability}{section.4.1}% 83
\BOOKMARK [2][-]{subsection.4.1.5}{Fine-mapping using summary statistics}{section.4.1}% 84
\BOOKMARK [1][-]{section.4.2}{Aims}{chapter.4}% 85
\BOOKMARK [1][-]{section.4.3}{Results}{chapter.4}% 86
\BOOKMARK [2][-]{subsection.4.3.1}{Psoriasis and healthy controls: cohort description and datasets}{section.4.3}% 87
\BOOKMARK [2][-]{subsection.4.3.2}{Investigation of psoriasis-specific changes in the enhancer mark H3K27ac in peripheral blood immune cell populations}{section.4.3}% 88
\BOOKMARK [2][-]{subsection.4.3.3}{Interrogation of chromatin accessibility changes in psoriasis peripheral blood immune cells}{section.4.3}% 89
\BOOKMARK [2][-]{subsection.4.3.4}{Differential gene expression analysis in circulating immune cells in psoriasis}{section.4.3}% 90
\BOOKMARK [2][-]{subsection.4.3.5}{RNA-seq in epidermis from psoriasis patients}{section.4.3}% 91
\BOOKMARK [2][-]{subsection.4.3.6}{Comparison of systemic and tissue specific gene expression signatures in psoriasis}{section.4.3}% 92
\BOOKMARK [2][-]{subsection.4.3.7}{Integration of chromatin accessibility and expression data for peripheral blood immune cells in psoriasis}{section.4.3}% 93
\BOOKMARK [2][-]{subsection.4.3.8}{Fine-mapping of psoriasis GWAS loci and functional interpretation}{section.4.3}% 94
\BOOKMARK [2][-]{subsection.4.3.9}{Allele-specific differences in chromatin accessibility at the GWAS locus 2p15}{section.4.3}% 95
\BOOKMARK [1][-]{section.4.4}{Discussion}{chapter.4}% 96
\BOOKMARK [2][-]{subsection.4.4.1}{Chromatin accessibility and H3K27ac landscape in psoriasis immune cells}{section.4.4}% 97
\BOOKMARK [2][-]{subsection.4.4.2}{Dysregulation of gene expression in psoriasis circulating immune cells}{section.4.4}% 98
\BOOKMARK [2][-]{subsection.4.4.3}{Integration of chromatin accessibility and gene expression data}{section.4.4}% 99
\BOOKMARK [2][-]{subsection.4.4.4}{Trancriptomic profiles in lesional and uninvolved psoriatic epidermis}{section.4.4}% 100
\BOOKMARK [2][-]{subsection.4.4.5}{LncRNAs in psoriasis}{section.4.4}% 101
\BOOKMARK [2][-]{subsection.4.4.6}{Fine-mapping using summary statistics and integration with epigenetic data}{section.4.4}% 102
\BOOKMARK [2][-]{subsection.4.4.7}{Limitations in the approach}{section.4.4}% 103
\BOOKMARK [1][-]{section.4.5}{Conclusions}{chapter.4}% 104
\BOOKMARK [0][-]{chapter*.127}{Bibliography}{}% 105
